Journal info
|
||
Select Journal
Journals
Bratislava Medical Journal Endocrine Regulations General Physiology and Biophysics Neoplasma 2024 Ahead of print 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 Acta Virologica Studia Psychologica Cardiology Letters Psychológia a patopsych. dieťaťa Kovove Materialy-Metallic Materials Slovenská hudbaWebshop Cart
Your Cart is currently empty.
Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.
Neoplasma Vol.58, No.3, p.211-216, 2011 |
||
Title: Overexpression of B cell-activating factor (BAFF) in neutrophils of oral cavity cancer patients – preliminary study | ||
Author: E. JABLONSKA, B. SLODCZYK, N. WAWRUSIEWICZ-KURYLONEK, M. GARLEY, D. DZIEMIANCZYK, A. KRETOWSKI, S. Z. GRABOWSKA | ||
Abstract: In the present study the expression of tumor-promoting B cell-activating factor (BAFF), a member of the tumor necrosis factor superfamily (TNF) in neutrophils from oral cavity cancer patients, was examined by real-time PCR. For the purpose of comparison, the expression of BAFF protein was assessed in autologous peripheral blood mononuclear cells (PBMCs). An important question of this study has also been to explain the role of NF-κB in the induction of BAFF molecule. The increased expression of BAFF at the mRNA and protein levels in neutrophils and mononuclear cells of patients before and after treatment were accompanied by the increased expression of phospho-IκB protein level. Demonstrated excessive expression and secretion of BAFF by examined leukocytes suggest a tumor-promoting activity of those cells in oral cavity cancer patients. The overexpression of BAFF, observed at mRNA and protein levels in PMNs and PBMCs, as well as the secretion of soluble form of sBAFF by these cells, accompany the increased concentrations of sBAFF in the serum of patients. Observations above suggest that the modulation of BAFF molecules in examined leukocytes and the levels thereof in the serum may have future implications for immunotherapy of oral cavity cancer patients. |
||
Keywords: oral cavity cancer, BAFF, PMNs, PBMCs | ||
Year: 2011, Volume: 58, Issue: 3 | Page From: 211, Page To: 216 | |
doi:10.4149/neo_2011_03_211 |
||
|
download file |
|